1. US Food and Drug Administration. March 15, 2024: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. fda.gov, https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-15-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03152024 (accessed 19 March 2024).
2. Sokolic, R. Oncologic Drugs Advisory Committee Meeting Introductory Comments. Ciltacabtagene Autoleucel. fda.org, https://www.fda.gov/media/177057/download (2024).
3. Sokolic, R. Oncologic Drugs Advisory Committee Meeting Introductory Comments. Idecabtagene Vicleucel (ide-cel). fda.gov, https://www.fda.gov/media/177060/download (2024).
4. Olivier, T., Haslam, A. & Prasad, V. Reporting of physicians’ or investigators’ choice of treatment in oncology randomized clinical trials. JAMA Netw. Open 5, e2144770 (2022).
5. ODAC. March 15, 2024 Oncologic Drugs Advisory Committe Meeting. fdazoomgov.com, https://go.nature.com/4baYsLo (2024).